RARE DISEASES A–Z · LETTER G
Gaucher Disease
Gaucher disease is the most common lysosomal storage disorder. An inherited shortage of the enzyme glucocerebrosidase means a fatty substance cannot be broken down and instead fills the scavenger cells of the spleen, liver, and bone marrow.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
Macrophages are the clean-up cells of the immune system, constantly digesting worn-out cell membranes. Without enough glucocerebrosidase, the fat glucocerebroside accumulates inside them, producing swollen 'Gaucher cells' that crowd the spleen, liver, and bone marrow. The spleen and liver enlarge — sometimes massively — while the crowded marrow underproduces blood cells, causing anaemia, infection risk, and bleeding from low platelets. Bone involvement is the most disabling feature for many: aching pain, sudden severe 'bone crises', weakened bones that fracture, and death of bone tissue at the hip or shoulder. Type 1, by far the commonest, spares the brain; the rarer types 2 and 3 involve the nervous system, mainly in children. Severity varies enormously, even within families.
How it works
Diagnosis is by a blood test measuring glucocerebrosidase enzyme activity, confirmed by genetic testing of the GBA1 gene. A biomarker (glucosylsphingosine, or lyso-Gb1) tracks disease burden and treatment response. Bone marrow examination is no longer needed for diagnosis in most cases, though Gaucher cells found there still sometimes provide the first clue. Assessment maps the burden: blood counts, spleen and liver volumes by MRI, bone density and skeletal imaging, and — because Gaucher disease travels with a higher risk of Parkinson disease and certain blood cancers in later life — a plan for long-term surveillance. Family screening is offered, as siblings have a 1-in-4 chance of being affected.
Day to day
Gaucher disease was the first lysosomal storage disorder to get enzyme replacement therapy, and it remains the standard: intravenous infusions, usually every two weeks, that shrink the spleen and liver, correct blood counts, and relieve bone symptoms over months to years. An oral alternative — substrate reduction therapy — reduces production of the stored fat in the first place and suits many adults with type 1 disease. Bone pain crises are managed with rest, fluids, and strong analgesia; fractures and dead bone may need orthopaedic surgery, and joint replacement outcomes are generally good. Treatment goals are now formalised (counts, organ sizes, bone health, quality of life) and monitored against the biomarker. Enzyme therapy does not reach the brain, so neurological types remain an area of active research.
When to get help
Reviews at a metabolic centre track blood counts, organ volumes, the biomarker, bone health, and growth in children. Report new bone pain promptly — a crisis needs assessment to exclude fracture or bone death — and mention unusual fatigue, bruising, or abdominal swelling between visits. Because of the Parkinson association, new tremor, stiffness, or acting out dreams in sleep deserves mention at review rather than being dismissed. Vaccinations should stay current, particularly if the spleen is very enlarged or has been removed (spleen removal is now avoided where possible precisely because it worsens bone disease). Genetic counselling supports testing and family-planning decisions.
Common questions
Who was Gaucher?
It is named after Philippe Gaucher, the French doctor who described the abnormal storage cells in a patient's spleen in 1882 — decades before the enzyme defect behind them was understood.
What are the types of Gaucher disease?
Type 1, the commonest form, spares the brain and is the type most often found in adults. Types 2 and 3 involve the nervous system: type 2 is severe in infancy, and type 3 causes slowly progressive neurological problems from childhood. Treatment decisions differ sharply by type.
Does enzyme therapy help the brain in Gaucher disease?
Enzyme treatment dramatically improves blood counts, spleen and liver size, and bone symptoms in type 1 disease. However, the infused enzyme does not cross into the brain, so it does not treat the neurological features of types 2 and 3 — one of the field's central challenges.
Why is Gaucher disease more common in some families?
Gaucher disease is more common in people of Ashkenazi Jewish ancestry, where carrier rates are relatively high, though it occurs in all populations. Carrier screening is available and sometimes offered in family planning for this population.
More in Letter G
Related
Sources
- Gaucher Disease (MedlinePlus)
- Gaucher Disease — MedlinePlus Genetics (MedlinePlus)
- Gaucher Disease (National Organization for Rare Disorders (NORD))
- Gaucher Disease — Genetic and Rare Diseases Information Center (NIH GARD)
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Enzyme and substrate therapy choices are individual; follow your metabolic centre's plan.